Robert Flavell, MD, PhD
This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody (\[89Zr\]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.
PRIMARY OBJECTIVE: I. To descriptively report patterns of \[89Zr\]DFO-YS5 uptake on whole-body PET. SECONDARY OBJECTIVE: II. To determine the safety of \[89Zr\]DFO-YS5. OUTLINE: Participants will be administered a single dose of \[89Zr\]DFO-YS5 followed by whole-body positron emission tomography (PET) imaging at a single time point. All participants will be followed for adverse events for approximately Participants in the main study will be followed for adverse events for approximately 1 month after \[89Zr\]DFO-YS5 radiotracer administration.
Inclusion Criteria: 1. Histological or cytological confirmation of malignant peripheral nerve sheath tumor, bladder cancer, or solid tumor neoplasm. 2. At least one soft tissue lesion measurable at 1 cm or greater in short axis measurement on cross sectional imaging such as Computerized tomography (CT), magnetic resonance imaging (MRI), or Positron Emission Tomography (PET)/CT (scan imaging as documented in the medical record). Exception: For participants with localized bladder cancer (pre-cystectomy), lesions smaller than 1 centimeter (cm) are permitted, provided there is cystoscopic confirm…
Given intravenously (IV)
Participants may receive a whole-body PET-MRI or a whole body PET-CT
Participants may receive a whole-body PET-CT or a whole-body PET-MRI
Arctuva estimate
Verify or correct the compensation shown for this listing.